晚期甲状腺癌靶向药物不良反应管理专家共识(2023年版)  

Expert consensus on the management of adverse events in patients receiving targeted agents for advanced thyroid cancer(2023 edition)

作　　者：薛丽琼 郭晔 陈立波 XUE Liqiong;GUO Ye;CHEN Libo(Thyroid Cancer Committee of Chinese Society of Clinical Oncology)

机构地区：[1]中国临床肿瘤学会甲状腺癌专家委员会

出　　处：《中国癌症杂志》2023年第9期879-888,共10页China Oncology

摘　　要：近年来,靶向治疗已成为晚期甲状腺癌的标准治疗方法。虽然中国临床肿瘤学会甲状腺癌专家委员会在2018年出版了针对放射性碘难治性分化型甲状腺癌(radioactive iodine-refractory differentiated thyroid cancer,RAIR-DTC)的靶向药物不良反应专家共识,但目前靶向治疗获批的类型已延伸至甲状腺髓样癌(medullary thyroid cancer,MTC)和甲状腺未分化癌(anaplastic thyroid cancer,ATC),靶向药物也从多靶点激酶抑制剂(multikinase inhibitors,MKIs)延伸至BRAF抑制剂、MEK抑制剂、RET抑制剂和TRK抑制剂。随着多种不同作用机制的靶向药物在临床上的广泛应用,并且考虑到众多来自不同科室的医师涉及晚期甲状腺癌的靶向治疗,靶向药物的不良反应管理急需不断规范和完善。因此,中国临床肿瘤学会甲状腺癌专家委员会组织专家组进行深入探讨,共同制定了本专家共识,旨在形成相对规范统一的认识,更好地指导临床实践。Recently,targeted therapy has become the standard of care for advanced thyroid cancer.Although expert consensus on the management of adverse events in patients receiving targeted agents for radioactive iodine-refractory differentiated thyroid cancer(RAIR-DTC)was formulated by Thyroid Cancer Committee of Chinese Society of Clinical Oncology in 2018,the tumor types which are eligible for targeted therapy have been extended to medullary thyroid cancer(MTC)and anaplastic thyroid cancer(ATC),and targeted agents have been approved from multikinase inhibitors(MKIs)to BRAF inhibitors,MEK inhibitors,RET inhibitors and TRK inhibitors.Along with the widely used targeted agents with different mechanism,the management of adverse events for targeted agents needs to be standardized and improved,especially considering the specialties of the physicians who are involved in the targeted therapy for thyroid cancer are variable.Therefore,Thyroid Cancer Committee of Chinese Society of Clinical Oncology convened an expert task force charged with developing consensus to serves as a guidance to standardize utilization of targeted agents and to optimize clinical practice.

关 键 词：晚期甲状腺癌 靶向药物 不良反应 专家共识 

分 类 号：R736.1[医药卫生—肿瘤]